Human Genome’s Lupus Drug Surprises Analysts
Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial.
h. thomas watkins
Positive Results for Human Genome’s Lupus Drug Benlysta
Biotechnology company Human Genome Sciences reported that its drug candidate Benlysta reduced symptoms of lupus in a long-term clinical trial.